ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/omet12943ometendo-12943Research ArticleОБЗОРЫREVIEWSМетаболизм витамина D при диабетической нефропатииVitamin D metabolism in diabetic nephropathyhttps://orcid.org/0000-0003-3287-571XАбиловЗ. В.AbilovZ. V.

Абилов Заур Вафалаил оглы

117292, Москва, ул. Дм. Ульянова, д. 11

Zaur V. Abilov - MD.

11, Dm. Ulyanova street, 117292 Moscow

zaur@internet.ruhttps://orcid.org/0000-0001-8694-9679СалимхановР. Х.SalimkhanovR. Kh.

Салимханов Рустам Халилович

Москва

Rustam Kh. Salimkhanov - MD.

Moscow

rustam.salimkhanov@gmail.comhttps://orcid.org/0000-0002-7634-5457ПоваляеваА. А.PovaliaevaA. A.

Поваляева Александра Александровна - к.м.н.

Москва

Alexandra A. Povaliaeva - MD, PhD.

Moscow

a.petrushkina@yandex.ruhttps://orcid.org/0000-0002-2729-9386ЖуковА. Ю.ZhukovA. Yu.

Жуков Артем Юрьевич

Москва

Artem Yu. Zhukov - MD.

Moscow

zhukovartem@yahoo.comhttps://orcid.org/0000-0001-6539-466XПигароваЕ. А.PigarovaE. A.

Пигарова Екатерина Александровна - д.м.н.

Москва

Ekaterina A. Pigarova - MD, PhD.

Moscow

kpigarova@gmail.comhttps://orcid.org/0000-0002-0327-4619ДзерановаЛ. К.DzeranovaL. K.

Дзеранова Лариса Константиновна - д.м.н.

Москва

Larisa K. Dzeranova - MD, PhD.

Moscow

dzeranovalk@yandex.ruhttps://orcid.org/0000-0001-7041-0732РожинскаяЛ. Я.RozhinskayaL. Ya.

Рожинская Людмила Яковлевна - д.м.н., профессор.

Москва

Liudmila Ya. Rozhinskaya - MD, PhD, Professor.

Moscow

lrozhinskaya@gmail.comНациональный медицинский исследовательский центр эндокринологииРоссияEndocrinology Research CentreRussian Federation202322012024204283290Copyright © Абилов З.В., Салимханов Р.Х., Поваляева А.А., Жуков А.Ю., Пигарова Е.А., Дзеранова Л.К., Рожинская Л.Я., 20242024Абилов З.В., Салимханов Р.Х., Поваляева А.А., Жуков А.Ю., Пигарова Е.А., Дзеранова Л.К., Рожинская Л.Я.Abilov Z.V., Salimkhanov R.K., Povaliaeva A.A., Zhukov A.Y., Pigarova E.A., Dzeranova L.K., Rozhinskaya L.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/12943

Диабетическая нефропатия (ДН) — специфическое поражение почек при сахарном диабете (СД), обусловленное воздействием гемодинамических и метаболических факторов. Именно в почках происходит важный этап метаболизма витамина D — 1α-гидроксилирование, в результате которого образуется его основная биологически активная форма. Снижение количества функционирующих нефронов при ДН приводит к нарушению метаболизма витамина D, способствуя развитию ряда осложнений. В представленном обзоре мы подробно остановились как на нормальном метаболизме витамина D, так и на особенностях метаболизма витамина D в условиях хронической болезни почек (ХБП). ДН — самая распространенная причина ХБП и, как следствие, трансплантации почек, а также одна из ведущих причин сердечно-сосудистой заболеваемости и смертности у пациентов с СД. Минеральные и костные нарушения вследствие ХБП, обусловленные патологическим метаболизмом витамина D, также являются независимыми факторами высокой смертности среди пациентов с ДН. Заключительная часть нашего обзора кратко освещает современные подходы к терапии витамином D в условиях ХБП, и в частности ДН. Стоит отметить, что, вопреки растущему числу пациентов с ДН, в настоящее время отсутствует единый взгляд на применение витамина D в качестве терапевтического средства при данной патологии.

Diabetic nephropathy (DN) is a specific kidney involvement in diabetes mellitus (DM), caused by hemodynamic and metabolic factors. In the kidneys takes place an important step in the metabolism of vitamin D — 1α-hydroxylation, which results in the formation of its biologically active form. Reduced number of functioning nephrons in DN leads to impaired vitamin D metabolism, contributing to the development of a number of complications. In this review, we have focused in detail on both normal vitamin D metabolism and the features of vitamin D metabolism in chronic kidney disease (CKD). DN is the most common cause of CKD and, as a consequence, of kidney transplantation and one of the leading causes of cardiovascular morbidity and mortality in patients with DM. Bone mineral disorders resulting from abnormal vitamin D metabolism are also independent factors of high mortality among patients with DM. The final part of our review briefly highlights current approaches to vitamin D therapy in CKD and, in particular, in DN. It is worth noting that, despite the increasing number of patients with DN, there is currently no unified view on the use of vitamin D as a therapeutic agent in this pathology.

витамин Dметаболизм витамина Dдиабетическая нефропатияхроническая болезнь почекколекальциферолальфакальцидолпарикальцитолvitamin Dvitamin D metabolismdiabetic nephropathychronic kidney diseasecholecalciferolalfacalcidolparicalcitolПоисково-аналитическая работа по подготовке рукописи проведена при поддержке Российского научного фонда (проект № 19-15-00243-П)ReferencesNgai M, Lin V, Wong HC, et al. Vitamin D status and its association with mineral and bone disorder in a multi-ethnic chronic kidney disease population. Clin Nephrol. 2014;82 (2014)(10):231-239. doi: https://doi.org/10.5414/CN108182Ngai M, Lin V, Wong HC, et al. Vitamin D status and its association with mineral and bone disorder in a multi-ethnic chronic kidney disease population. Clin Nephrol. 2014;82 (2014)(10):231-239. doi: https://doi.org/10.5414/CN108182Gross JL, de Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164-176. doi: https://doi.org/10.2337/diacare.28.1.164Gross JL, de Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164-176. doi: https://doi.org/10.2337/diacare.28.1.164Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease. Nat Rev Dis Prim. 2015;1(1):15018. doi: https://doi.org/10.1038/nrdp.2015.18Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease. Nat Rev Dis Prim. 2015;1(1):15018. doi: https://doi.org/10.1038/nrdp.2015.18Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302-308. doi: https://doi.org/10.1681/ASN.2012070718Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302-308. doi: https://doi.org/10.1681/ASN.2012070718Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 [published correction appears in Lancet. 2013;381(9867):628].Lancet. 2012;380(9859):2095-2128. doi: https://doi.org/10.1016/S0140-6736(12)61728-0Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 [published correction appears in Lancet. 2013;381(9867):628].Lancet. 2012;380(9859):2095-2128. doi: https://doi.org/10.1016/S0140-6736(12)61728-0Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives [published correction appears in Lancet. 2013;382(9888):208]. Lancet. 2013;382(9888):260-272. doi: https://doi.org/10.1016/S0140-6736(13)60687-XJha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives [published correction appears in Lancet. 2013;382(9888):208]. Lancet. 2013;382(9888):260-272. doi: https://doi.org/10.1016/S0140-6736(13)60687-XMirković K, van den Born J, Navis G, de Borst MH. Vitamin D in chronic kidney disease: new potential for intervention. Curr Drug Targets. 2011;12(1):42-53. doi: https://doi.org/10.2174/138945011793591572Mirković K, van den Born J, Navis G, de Borst MH. Vitamin D in chronic kidney disease: new potential for intervention. Curr Drug Targets. 2011;12(1):42-53. doi: https://doi.org/10.2174/138945011793591572Saponaro F, Saba A, Zucchi R. An update on vitamin D metabolism. Int J Mol Sci. 2020;21(18):6573. doi: https://doi.org/10.3390/ijms21186573Saponaro F, Saba A, Zucchi R. An update on vitamin D metabolism. Int J Mol Sci. 2020;21(18):6573. doi: https://doi.org/10.3390/ijms21186573Mitsche MA, McDonald JG, Hobbs HH, Cohen JC. Flux analysis of cholesterol biosynthesis in vivo reveals multiple tissue and cell-type specific pathways. Elife. 2015;(4):e07999. doi: https://doi.org/10.7554/eLife.07999Mitsche MA, McDonald JG, Hobbs HH, Cohen JC. Flux analysis of cholesterol biosynthesis in vivo reveals multiple tissue and cell-type specific pathways. Elife. 2015;(4):e07999. doi: https://doi.org/10.7554/eLife.07999Bikle DD. Vitamin D: production, metabolism and mechanisms of action. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext. South Dartmouth (MA): MDText. com, Inc.; 2021.Bikle DD. Vitamin D: production, metabolism and mechanisms of action. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext. South Dartmouth (MA): MDText. com, Inc.; 2021.Miller WL, Portale AA. Vitamin D 1 alpha-hydroxylase. Trends Endocrinol Metab. 2000;11(8):315-319. doi: https://doi.org/10.1016/s1043-2760(00)00287-3Miller WL, Portale AA. Vitamin D 1 alpha-hydroxylase. Trends Endocrinol Metab. 2000;11(8):315-319. doi: https://doi.org/10.1016/s1043-2760(00)00287-3Holick MF. Resurrection of vitamin D deficiency and rickets. J Clin Invest. 2006;116(8):2062-2072. doi: https://doi.org/10.1172/JCI29449Holick MF. Resurrection of vitamin D deficiency and rickets. J Clin Invest. 2006;116(8):2062-2072. doi: https://doi.org/10.1172/JCI29449Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005;289(1):F8-F28. doi: https://doi.org/10.1152/ajprenal.00336.2004Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005;289(1):F8-F28. doi: https://doi.org/10.1152/ajprenal.00336.2004Hewison M, Zehnder D, Chakraverty R, Adams JS. Vitamin D and barrier function: a novel role for extra-renal 1 alphahydroxylase. Mol Cell Endocrinol. 2004;215(1-2):31-38. doi: https://doi.org/10.1016/j.mce.2003.11.017Hewison M, Zehnder D, Chakraverty R, Adams JS. Vitamin D and barrier function: a novel role for extra-renal 1 alphahydroxylase. Mol Cell Endocrinol. 2004;215(1-2):31-38. doi: https://doi.org/10.1016/j.mce.2003.11.017Jones G, Prosser DE, Kaufmann M. 25-Hydroxyvitamin D-24hydroxylase (CYP24A1): its important role in the degradation of vitamin D. Arch Biochem Biophys. 2012;523(1):9-18. doi: https://doi.org/10.1016/j.abb.2011.11.003Jones G, Prosser DE, Kaufmann M. 25-Hydroxyvitamin D-24hydroxylase (CYP24A1): its important role in the degradation of vitamin D. Arch Biochem Biophys. 2012;523(1):9-18. doi: https://doi.org/10.1016/j.abb.2011.11.003Blau JE, Collins MT. The PTH-Vitamin D-FGF23 axis. Rev Endocr Metab Disord. 2015;16(2):165-174. doi: https://doi.org/10.1007/s11154-015-9318-zBlau JE, Collins MT. The PTH-Vitamin D-FGF23 axis. Rev Endocr Metab Disord. 2015;16(2):165-174. doi: https://doi.org/10.1007/s11154-015-9318-zJones G, Prosser DE, Kaufmann M. Cytochrome P450-mediated metabolism of vitamin D. J Lipid Res. 2014;55(1):13-31. doi: https://doi.org/10.1194/jlr.R031534Jones G, Prosser DE, Kaufmann M. Cytochrome P450-mediated metabolism of vitamin D. J Lipid Res. 2014;55(1):13-31. doi: https://doi.org/10.1194/jlr.R031534Dusso A, González EA, Martin KJ. Vitamin D in chronic kidney disease. Best Pract Res Clin Endocrinol Metab. 2011;25(4):647-655. doi: https://doi.org/10.1016/j.beem.2011.05.005Dusso A, González EA, Martin KJ. Vitamin D in chronic kidney disease. Best Pract Res Clin Endocrinol Metab. 2011;25(4):647-655. doi: https://doi.org/10.1016/j.beem.2011.05.005Plum LA, Zella JB. Vitamin D compounds and diabetic nephropathy. Arch Biochem Biophys. 2012;523(1):87-94. doi: https://doi.org/10.1016/j.abb.2012.02.008Plum LA, Zella JB. Vitamin D compounds and diabetic nephropathy. Arch Biochem Biophys. 2012;523(1):87-94. doi: https://doi.org/10.1016/j.abb.2012.02.008Dusso AS, Tokumoto M. Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease. Kidney Int. 2011;79(7):715-729. doi: https://doi.org/10.1038/ki.2010.543Dusso AS, Tokumoto M. Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease. Kidney Int. 2011;79(7):715-729. doi: https://doi.org/10.1038/ki.2010.543Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease [published correction appears in Kidney Int. 2009;75(11):1237]. Kidney Int. 2007;71(1):31-38. doi: https://doi.org/10.1038/sj.ki.5002009Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease [published correction appears in Kidney Int. 2009;75(11):1237]. Kidney Int. 2007;71(1):31-38. doi: https://doi.org/10.1038/sj.ki.5002009Larsson T, Nisbeth U, Ljunggren O, et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003;64(6):2272-2279. doi: https://doi.org/10.1046/j.1523-1755.2003.00328.xLarsson T, Nisbeth U, Ljunggren O, et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003;64(6):2272-2279. doi: https://doi.org/10.1046/j.1523-1755.2003.00328.xNigwekar SU, Tamez H, Thadhani RI. Vitamin D and chronic kidney disease-mineral bone disease (CKD-MBD). Bonekey Rep. 2014;(3):498. doi: https://doi.org/10.1038/bonekey.2013.232Nigwekar SU, Tamez H, Thadhani RI. Vitamin D and chronic kidney disease-mineral bone disease (CKD-MBD). Bonekey Rep. 2014;(3):498. doi: https://doi.org/10.1038/bonekey.2013.232Povaliaeva AA, Pigarova EA, Romanova AA, et al. Vitamin D-binding protein: multifunctional component of blood serum. Annals of the Russian academy of medical sciences. 2021;76(1):103-110. doi: https://doi.org/10.15690/vramn1396Povaliaeva AA, Pigarova EA, Romanova AA, et al. Vitamin D-binding protein: multifunctional component of blood serum. Annals of the Russian academy of medical sciences. 2021;76(1):103-110. doi: https://doi.org/10.15690/vramn1396Khan SS, Petkovich M, Holden RM, Adams MA. Megalin and vitamin D metabolism-implications in non-renal tissues and kidney disease. Nutrients. 2022;14(18):3690. doi: https://doi.org/10.3390/nu14183690Khan SS, Petkovich M, Holden RM, Adams MA. Megalin and vitamin D metabolism-implications in non-renal tissues and kidney disease. Nutrients. 2022;14(18):3690. doi: https://doi.org/10.3390/nu14183690Hilpert J, Wogensen L, Thykjaer T, et al. Expression profiling confirms the role of endocytic receptor megalin in renal vitamin D3 metabolism. Kidney Int. 2002;62(5):1672-1681. doi: https://doi.org/10.1046/j.1523-1755.2002.00634.xHilpert J, Wogensen L, Thykjaer T, et al. Expression profiling confirms the role of endocytic receptor megalin in renal vitamin D3 metabolism. Kidney Int. 2002;62(5):1672-1681. doi: https://doi.org/10.1046/j.1523-1755.2002.00634.xMehrotra R, Kermah D, Budoff M, et al. Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(4):1144-1151. doi: https://doi.org/10.2215/CJN.05781207Mehrotra R, Kermah D, Budoff M, et al. Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(4):1144-1151. doi: https://doi.org/10.2215/CJN.05781207Leheste JR, Rolinski B, Vorum H, et al. Megalin knockout mice as an animal model of low molecular weight proteinuria. Am J Pathol. 1999;155(4):1361-1370. doi: https://doi.org/10.1016/S0002-9440(10)65238-8Leheste JR, Rolinski B, Vorum H, et al. Megalin knockout mice as an animal model of low molecular weight proteinuria. Am J Pathol. 1999;155(4):1361-1370. doi: https://doi.org/10.1016/S0002-9440(10)65238-8Liu W, Yu WR, Carling T, et al. Regulation of gp330/megalin expression by vitamins A and D. Eur J Clin Invest. 1998;28(2):100-107. doi: https://doi.org/10.1046/j.1365-2362.1998.00253.xLiu W, Yu WR, Carling T, et al. Regulation of gp330/megalin expression by vitamins A and D. Eur J Clin Invest. 1998;28(2):100-107. doi: https://doi.org/10.1046/j.1365-2362.1998.00253.xNielsen R, Christensen EI, Birn H. Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease. Kidney Int. 2016;89(1):58-67. doi: https://doi.org/10.1016/j.kint.2015.11.007Nielsen R, Christensen EI, Birn H. Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease. Kidney Int. 2016;89(1):58-67. doi: https://doi.org/10.1016/j.kint.2015.11.007Nykjaer A, Fyfe JC, Kozyraki R, et al. Cubilin dysfunction causes abnormal metabolism of the steroid hormone 25(OH) vitamin D(3). Proc Natl Acad Sci U S A. 2001;98(24):13895-13900. doi: https://doi.org/10.1073/pnas.241516998Nykjaer A, Fyfe JC, Kozyraki R, et al. Cubilin dysfunction causes abnormal metabolism of the steroid hormone 25(OH) vitamin D(3). Proc Natl Acad Sci U S A. 2001;98(24):13895-13900. doi: https://doi.org/10.1073/pnas.241516998Usatii M, Rousseau L, Demers C, et al. Parathyroid hormone fragments inhibit active hormone and hypocalcemia-induced 1,25(OH)2D synthesis. Kidney Int. 2007;72(11):1330-1335. doi: https://doi.org/10.1038/sj.ki.5002532Usatii M, Rousseau L, Demers C, et al. Parathyroid hormone fragments inhibit active hormone and hypocalcemia-induced 1,25(OH)2D synthesis. Kidney Int. 2007;72(11):1330-1335. doi: https://doi.org/10.1038/sj.ki.5002532Chen W, Roncal-Jimenez C, Lanaspa M, et al. Uric acid suppresses 1 alpha hydroxylase in vitro and in vivo. Metabolism. 2014;63(1):150-160. doi: https://doi.org/10.1016/j.metabol.2013.09.018Chen W, Roncal-Jimenez C, Lanaspa M, et al. Uric acid suppresses 1 alpha hydroxylase in vitro and in vivo. Metabolism. 2014;63(1):150-160. doi: https://doi.org/10.1016/j.metabol.2013.09.018Mauer M, Doria A. Uric acid and diabetic nephropathy risk. Contrib Nephrol. 2018;(192):103-109. doi: https://doi.org/10.1159/000484284Mauer M, Doria A. Uric acid and diabetic nephropathy risk. Contrib Nephrol. 2018;(192):103-109. doi: https://doi.org/10.1159/000484284Michaud J, Naud J, Ouimet D, et al. Reduced hepatic synthesis of calcidiol in uremia. J Am Soc Nephrol. 2010;21(9):1488-1497. doi: https://doi.org/10.1681/ASN.2009080815Michaud J, Naud J, Ouimet D, et al. Reduced hepatic synthesis of calcidiol in uremia. J Am Soc Nephrol. 2010;21(9):1488-1497. doi: https://doi.org/10.1681/ASN.2009080815Zehnder D, Bland R, Williams MC, et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alphahydroxylase. J Clin Endocrinol Metab. 2001;86(2):888-894. doi: https://doi.org/10.1210/jcem.86.2.7220Zehnder D, Bland R, Williams MC, et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alphahydroxylase. J Clin Endocrinol Metab. 2001;86(2):888-894. doi: https://doi.org/10.1210/jcem.86.2.7220Xiao X, Wang Y, Hou Y, et al. Vitamin D deficiency and related risk factors in patients with diabetic nephropathy. J Int Med Res. 2016;44(3):673-684. doi: https://doi.org/10.1177/0300060515593765Xiao X, Wang Y, Hou Y, et al. Vitamin D deficiency and related risk factors in patients with diabetic nephropathy. J Int Med Res. 2016;44(3):673-684. doi: https://doi.org/10.1177/0300060515593765Derakhshanian H, Shab-Bidar S, Speakman JR, Nadimi H, Djafarian K. Vitamin D and diabetic nephropathy: A systematic review and meta-analysis. Nutrition. 2015;31(10):1189-1194. doi: https://doi.org/10.1016/j.nut.2015.04.009Derakhshanian H, Shab-Bidar S, Speakman JR, Nadimi H, Djafarian K. Vitamin D and diabetic nephropathy: A systematic review and meta-analysis. Nutrition. 2015;31(10):1189-1194. doi: https://doi.org/10.1016/j.nut.2015.04.009Usluogullari CA, Balkan F, Caner S, et al. The relationship between microvascular complications and vitamin D deficiency in type 2 diabetes mellitus. BMC Endocr Disord. 2015;15(1):33. doi: https://doi.org/10.1186/s12902-015-0029-yUsluogullari CA, Balkan F, Caner S, et al. The relationship between microvascular complications and vitamin D deficiency in type 2 diabetes mellitus. BMC Endocr Disord. 2015;15(1):33. doi: https://doi.org/10.1186/s12902-015-0029-yHong SH, Kim YB, Choi HS, et al. Association of Vitamin D deficiency with diabetic nephropathy. Endocrinol Metab (Seoul). 2021;36(1):106-113. doi: https://doi.org/10.3803/EnM.2020.826Hong SH, Kim YB, Choi HS, et al. Association of Vitamin D deficiency with diabetic nephropathy. Endocrinol Metab (Seoul). 2021;36(1):106-113. doi: https://doi.org/10.3803/EnM.2020.826de Boer IH, Sachs MC, Cleary PA, et al. Circulating vitamin D metabolites and kidney disease in type 1 diabetes. J Clin Endocrinol Metab. 2012;97(12):4780-4788. doi: https://doi.org/10.1210/jc.2012-2852de Boer IH, Sachs MC, Cleary PA, et al. Circulating vitamin D metabolites and kidney disease in type 1 diabetes. J Clin Endocrinol Metab. 2012;97(12):4780-4788. doi: https://doi.org/10.1210/jc.2012-2852Senyigit A. The association between 25-hydroxy vitamin D deficiency and diabetic complications in patients with type 2 diabetes mellitus. Diabetes Metab Syndr. 2019;13(2):1381-1386. doi: https://doi.org/10.1016/j.dsx.2019.01.043Senyigit A. The association between 25-hydroxy vitamin D deficiency and diabetic complications in patients with type 2 diabetes mellitus. Diabetes Metab Syndr. 2019;13(2):1381-1386. doi: https://doi.org/10.1016/j.dsx.2019.01.043Zhao WJ, Xia XY, Yin J. Relationship of serum vitamin D levels with diabetic microvascular complications in patients with type 2 diabetes mellitus. Chin Med J (Engl). 2021;134(7):814-820. doi: https://doi.org/10.1097/CM9.0000000000001364Zhao WJ, Xia XY, Yin J. Relationship of serum vitamin D levels with diabetic microvascular complications in patients with type 2 diabetes mellitus. Chin Med J (Engl). 2021;134(7):814-820. doi: https://doi.org/10.1097/CM9.0000000000001364Xiao X, Wang Y, Hou Y, et al. Vitamin D deficiency and related risk factors in patients with diabetic nephropathy. J Int Med Res. 2016;44(3):673-684. doi: https://doi.org/10.1177/0300060515593765Xiao X, Wang Y, Hou Y, et al. Vitamin D deficiency and related risk factors in patients with diabetic nephropathy. J Int Med Res. 2016;44(3):673-684. doi: https://doi.org/10.1177/0300060515593765Fernández-Juárez G, Luño J, Barrio V, et al. 25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system. Clin J Am Soc Nephrol. 2013;8(11):1870-1876. doi: https://doi.org/10.2215/CJN.00910113Fernández-Juárez G, Luño J, Barrio V, et al. 25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system. Clin J Am Soc Nephrol. 2013;8(11):1870-1876. doi: https://doi.org/10.2215/CJN.00910113Fan L, Zhang Y, Zhu J, et al. Association of vitamin D deficiency with diabetic peripheral neuropathy and diabetic nephropathy in Tianjin, China. Asia Pac J Clin Nutr. 2018;27(3):599-606. doi: https://doi.org/10.6133/apjcn.062017.11Fan L, Zhang Y, Zhu J, et al. Association of vitamin D deficiency with diabetic peripheral neuropathy and diabetic nephropathy in Tianjin, China. Asia Pac J Clin Nutr. 2018;27(3):599-606. doi: https://doi.org/10.6133/apjcn.062017.11Ucak S, Sevim E, Ersoy D, et al. Evaluation of the relationship between microalbuminuria and 25-(OH) vitamin D levels in patients with type 2 diabetes mellitus. Aging Male. 2019;22(2):116-120. doi: https://doi.org/10.1080/13685538.2018.1479385Ucak S, Sevim E, Ersoy D, et al. Evaluation of the relationship between microalbuminuria and 25-(OH) vitamin D levels in patients with type 2 diabetes mellitus. Aging Male. 2019;22(2):116-120. doi: https://doi.org/10.1080/13685538.2018.1479385Jamal Shahwan M, Hassan NAG, Shaheen RA. Assessment of kidney function and associated risk factors among type 2 diabetic patients. Diabetes Metab Syndr. 2019;13(4):2661-2665. doi: https://doi.org/10.1016/j.dsx.2019.07.025Jamal Shahwan M, Hassan NAG, Shaheen RA. Assessment of kidney function and associated risk factors among type 2 diabetic patients. Diabetes Metab Syndr. 2019;13(4):2661-2665. doi: https://doi.org/10.1016/j.dsx.2019.07.025Ali MI, Fawaz LA, Sedik EE, et al. Vitamin D status in diabetic patients (type 2) and its relation to glycemic control & diabetic nephropathy. Diabetes Metab Syndr. 2019;13(3):1971-1973. doi: https://doi.org/10.1016/j.dsx.2019.04.040Ali MI, Fawaz LA, Sedik EE, et al. Vitamin D status in diabetic patients (type 2) and its relation to glycemic control & diabetic nephropathy. Diabetes Metab Syndr. 2019;13(3):1971-1973. doi: https://doi.org/10.1016/j.dsx.2019.04.040Mirković K, Doorenbos CR, Dam WA, et al. Urinary vitamin D binding protein: a potential novel marker of renal interstitial inflammation and fibrosis. PLoS One. 2013;8(2):e55887. doi: https://doi.org/10.1371/journal.pone.0055887Mirković K, Doorenbos CR, Dam WA, et al. Urinary vitamin D binding protein: a potential novel marker of renal interstitial inflammation and fibrosis. PLoS One. 2013;8(2):e55887. doi: https://doi.org/10.1371/journal.pone.0055887Aljack H, Abdalla M, Idris O, Ismail A. Vitamin D deficiency increases risk of nephropathy and cardiovascular diseases in Type 2 diabetes mellitus patients. J Res Med Sci. 2019;24(1):47. doi: https://doi.org/10.4103/jrms.JRMS_303_18Aljack H, Abdalla M, Idris O, Ismail A. Vitamin D deficiency increases risk of nephropathy and cardiovascular diseases in Type 2 diabetes mellitus patients. J Res Med Sci. 2019;24(1):47. doi: https://doi.org/10.4103/jrms.JRMS_303_18Derakhshanian H, Shab-Bidar S, Speakman JR, et al. Vitamin D and diabetic nephropathy: A systematic review and meta-analysis. Nutrition. 2015;31(10):1189-1194. doi: https://doi.org/10.1016/j.nut.2015.04.009Derakhshanian H, Shab-Bidar S, Speakman JR, et al. Vitamin D and diabetic nephropathy: A systematic review and meta-analysis. Nutrition. 2015;31(10):1189-1194. doi: https://doi.org/10.1016/j.nut.2015.04.009de Boer IH, Sachs MC, Cleary PA, et al. Circulating vitamin D metabolites and kidney disease in type 1 diabetes. J Clin Endocrinol Metab. 2012;97(12):4780-4788. doi: https://doi.org/10.1210/jc.2012-2852de Boer IH, Sachs MC, Cleary PA, et al. Circulating vitamin D metabolites and kidney disease in type 1 diabetes. J Clin Endocrinol Metab. 2012;97(12):4780-4788. doi: https://doi.org/10.1210/jc.2012-2852Metzger M, Houillier P, Gauci C, et al. Relation between circulating levels of 25(OH) vitamin D and parathyroid hormone in chronic kidney disease: quest for a threshold. J Clin Endocrinol Metab. 2013;98(7):2922-2928. doi: https://doi.org/10.1210/jc.2013-1294Metzger M, Houillier P, Gauci C, et al. Relation between circulating levels of 25(OH) vitamin D and parathyroid hormone in chronic kidney disease: quest for a threshold. J Clin Endocrinol Metab. 2013;98(7):2922-2928. doi: https://doi.org/10.1210/jc.2013-1294González EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol. 2004;24(5):503-510. doi: https://doi.org/10.1159/000081023González EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol. 2004;24(5):503-510. doi: https://doi.org/10.1159/000081023Taal MW, Thurston V, McIntyre NJ, et al. The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease. Kidney Int. 2014;86(2):407-413. doi: https://doi.org/10.1038/ki.2013.537Taal MW, Thurston V, McIntyre NJ, et al. The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease. Kidney Int. 2014;86(2):407-413. doi: https://doi.org/10.1038/ki.2013.537Shardlow A, McIntyre NJ, Fluck RJ, et al. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3. BMJ Open. 2017;7(8):e016528. doi: https://doi.org/10.1136/bmjopen-2017-016528Shardlow A, McIntyre NJ, Fluck RJ, et al. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3. BMJ Open. 2017;7(8):e016528. doi: https://doi.org/10.1136/bmjopen-2017-016528Bai X, Luo Q, Tan K, Guo L. Diagnostic value of VDBP and miR-155-5p in diabetic nephropathy and the correlation with urinary microalbumin. Exp Ther Med. 2020;20(5):86. doi: https://doi.org/10.3892/etm.2020.9214Bai X, Luo Q, Tan K, Guo L. Diagnostic value of VDBP and miR-155-5p in diabetic nephropathy and the correlation with urinary microalbumin. Exp Ther Med. 2020;20(5):86. doi: https://doi.org/10.3892/etm.2020.9214Fawzy MS, Abu AlSel BT. Assessment of vitamin D-binding protein and early prediction of nephropathy in type 2 Saudi diabetic patients. J Diabetes Res. 2018;2018:1-13. doi: https://doi.org/10.1155/2018/8517929Fawzy MS, Abu AlSel BT. Assessment of vitamin D-binding protein and early prediction of nephropathy in type 2 Saudi diabetic patients. J Diabetes Res. 2018;2018:1-13. doi: https://doi.org/10.1155/2018/8517929Shoukry A, Bdeer Sel-A, El-Sokkary RH. Urinary monocyte chemoattractant protein-1 and vitamin D-binding protein as biomarkers for early detection of diabetic nephropathy in type 2 diabetes mellitus. Mol Cell Biochem. 2015;408(1-2):25-35. doi: https://doi.org/10.1007/s11010-015-2479-yShoukry A, Bdeer Sel-A, El-Sokkary RH. Urinary monocyte chemoattractant protein-1 and vitamin D-binding protein as biomarkers for early detection of diabetic nephropathy in type 2 diabetes mellitus. Mol Cell Biochem. 2015;408(1-2):25-35. doi: https://doi.org/10.1007/s11010-015-2479-yTian XQ, Zhao LM, Ge JP, et al. Elevated urinary level of vitamin D-binding protein as a novel biomarker for diabetic nephropathy. Exp Ther Med. 2014;7(2):411-416. doi: https://doi.org/10.3892/etm.2013.1426Tian XQ, Zhao LM, Ge JP, et al. Elevated urinary level of vitamin D-binding protein as a novel biomarker for diabetic nephropathy. Exp Ther Med. 2014;7(2):411-416. doi: https://doi.org/10.3892/etm.2013.1426Hamzawy M, Gouda SAA, Rashid L, et al. The cellular selection between apoptosis and autophagy: roles of vitamin D, glucose and immune response in diabetic nephropathy. Endocrine. 2017;58(1):66-80. doi: https://doi.org/10.1007/s12020-017-1402-6Hamzawy M, Gouda SAA, Rashid L, et al. The cellular selection between apoptosis and autophagy: roles of vitamin D, glucose and immune response in diabetic nephropathy. Endocrine. 2017;58(1):66-80. doi: https://doi.org/10.1007/s12020-017-1402-6Yang M, Yang B, Gan H, et al. Anti-inflammatory effect of 1,25-dihydroxyvitamin D3 is associated with crosstalk between signal transducer and activator of transcription 5 and the vitamin D receptor in human monocytes. Exp Ther Med. 2015;9(5):1739-1744. doi: https://doi.org/10.3892/etm.2015.2321Yang M, Yang B, Gan H, et al. Anti-inflammatory effect of 1,25-dihydroxyvitamin D3 is associated with crosstalk between signal transducer and activator of transcription 5 and the vitamin D receptor in human monocytes. Exp Ther Med. 2015;9(5):1739-1744. doi: https://doi.org/10.3892/etm.2015.2321Wang Y, Deb DK, Zhang Z, et al. Vitamin D receptor signaling in podocytes protects against diabetic nephropathy. J Am Soc Nephrol. 2012;23(12):1977-1986. doi: https://doi.org/10.1681/ASN.2012040383Wang Y, Deb DK, Zhang Z, et al. Vitamin D receptor signaling in podocytes protects against diabetic nephropathy. J Am Soc Nephrol. 2012;23(12):1977-1986. doi: https://doi.org/10.1681/ASN.2012040383Kim MJ, Frankel AH, Donaldson M, et al. Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin–angiotensin– aldosterone system inhibition. Kidney Int. 2011;80(8):851-860. doi: https://doi.org/10.1038/ki.2011.224Kim MJ, Frankel AH, Donaldson M, et al. Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin–angiotensin– aldosterone system inhibition. Kidney Int. 2011;80(8):851-860. doi: https://doi.org/10.1038/ki.2011.224Zhang X, Zhou M, Guo Y, et al. 1,25-dihydroxyvitamin D 3 promotes high glucose-induced M1 macrophage switching to M2 via the VDR-PPAR γ signaling pathway. Biomed Res Int. 2015;2015:1-14. doi: https://doi.org/10.1155/2015/157834Zhang X, Zhou M, Guo Y, et al. 1,25-dihydroxyvitamin D 3 promotes high glucose-induced M1 macrophage switching to M2 via the VDR-PPAR γ signaling pathway. Biomed Res Int. 2015;2015:1-14. doi: https://doi.org/10.1155/2015/157834Nakhoul N, Thawko T, Farber E, et al. The therapeutic effect of active vitamin D supplementation in preventing the progression of diabetic nephropathy in a diabetic mouse model. J Diabetes Res. 2020;2020:1-10. doi: https://doi.org/10.1155/2020/7907605Nakhoul N, Thawko T, Farber E, et al. The therapeutic effect of active vitamin D supplementation in preventing the progression of diabetic nephropathy in a diabetic mouse model. J Diabetes Res. 2020;2020:1-10. doi: https://doi.org/10.1155/2020/7907605He W, Kang YS, Dai C, Liu Y. Blockade of Wnt/β-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J Am Soc Nephrol. 2011;22(1):90-103. doi: https://doi.org/10.1681/ASN.2009121236He W, Kang YS, Dai C, Liu Y. Blockade of Wnt/β-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J Am Soc Nephrol. 2011;22(1):90-103. doi: https://doi.org/10.1681/ASN.2009121236Zhang W, Yi B, Zhang K, et al. 1,25-(OH)2D3 and its analogue BXL-628 inhibit high glucose-induced activation of RhoA/ ROCK pathway in HK-2 cells. Exp Ther Med. 2017;13(5):1969-1976. doi: https://doi.org/10.3892/etm.2017.4211Zhang W, Yi B, Zhang K, et al. 1,25-(OH)2D3 and its analogue BXL-628 inhibit high glucose-induced activation of RhoA/ ROCK pathway in HK-2 cells. Exp Ther Med. 2017;13(5):1969-1976. doi: https://doi.org/10.3892/etm.2017.4211Zhang W, Yi B, Zhang K, et al. KDIGO 2017 Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) [published correction appears in Kidney Int Suppl. 2017;7(3):e1]. Kidney Int Suppl. 2017;7(1):1-59. doi: https://doi.org/10.1016/j.kisu.2017.04.001Zhang W, Yi B, Zhang K, et al. KDIGO 2017 Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) [published correction appears in Kidney Int Suppl. 2017;7(3):e1]. Kidney Int Suppl. 2017;7(1):1-59. doi: https://doi.org/10.1016/j.kisu.2017.04.001Levey AS, Coresh J, Bolton K, et al. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2S1):S1-S266.Levey AS, Coresh J, Bolton K, et al. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2S1):S1-S266.Pigarova EA, Rozhinskaya LY, Belaya JE, et al. Russian Association of Endocrinologists recommendations for diagnosis, treatment and prevention of vitamin D deficiency in adults. Problems of Endocrinology. 2016;62(4):60-84. doi: https://doi.org/10.14341/probl201662460-84Pigarova EA, Rozhinskaya LY, Belaya JE, et al. Russian Association of Endocrinologists recommendations for diagnosis, treatment and prevention of vitamin D deficiency in adults. Problems of Endocrinology. 2016;62(4):60-84. doi: https://doi.org/10.14341/probl201662460-84Ennis JL, Worcester EM, Coe FL, Sprague SM. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low. J Nephrol. 2016;29(1):63-70. doi: https://doi.org/10.1007/s40620-015-0186-0Ennis JL, Worcester EM, Coe FL, Sprague SM. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low. J Nephrol. 2016;29(1):63-70. doi: https://doi.org/10.1007/s40620-015-0186-0Ahmadi N, Mortazavi M, Iraj B, Askari G. Whether vitamin D3 is effective in reducing proteinuria in type 2 diabetic patients? J Res Med Sci. 2013;18(5):374-377.Ahmadi N, Mortazavi M, Iraj B, Askari G. Whether vitamin D3 is effective in reducing proteinuria in type 2 diabetic patients? J Res Med Sci. 2013;18(5):374-377.Bonakdaran S., Hami M., Hatefi A. The effects of calcitriol on albuminuria in patients with type-2 diabetes mellitus. Saudi J Kidney Dis.Transpl. 2012;23(6):1215-1220. doi: https://doi.org/10.4103/1319-2442.103562Bonakdaran S., Hami M., Hatefi A. The effects of calcitriol on albuminuria in patients with type-2 diabetes mellitus. Saudi J Kidney Dis.Transpl. 2012;23(6):1215-1220. doi: https://doi.org/10.4103/1319-2442.103562Liyanage P, Lekamwasam S, Weerarathna T, Liyanage C. Effect of Vitamin D therapy on urinary albumin excretion, renal functions, and plasma renin among patients with diabetic nephropathy: A randomized, double-blind clinical trial. J Postgrad Med. 2018;64(1):10. doi: https://doi.org/10.4103/jpgm.JPGM_598_16Liyanage P, Lekamwasam S, Weerarathna T, Liyanage C. Effect of Vitamin D therapy on urinary albumin excretion, renal functions, and plasma renin among patients with diabetic nephropathy: A randomized, double-blind clinical trial. J Postgrad Med. 2018;64(1):10. doi: https://doi.org/10.4103/jpgm.JPGM_598_16Liyanage G, Lekamwasam S, Weerarathna T, Liyanage C. Effect of vitamin D therapy on bone mineral density in patients with diabetic nephropathy; a randomized, double-blind placebo controlled clinical trial. J Diabetes Metab Disord. 2021;20(1):229-235. doi: https://doi.org/10.1007/s40200-021-00737-yLiyanage G, Lekamwasam S, Weerarathna T, Liyanage C. Effect of vitamin D therapy on bone mineral density in patients with diabetic nephropathy; a randomized, double-blind placebo controlled clinical trial. J Diabetes Metab Disord. 2021;20(1):229-235. doi: https://doi.org/10.1007/s40200-021-00737-yJoergensen C, Tarnow L, Goetze JP, Rossing P. Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type 1 diabetes mellitus and diabetic nephropathy: a randomized trial. Diabet Med. 2015;32(3):374-381. doi: https://doi.org/10.1111/dme.12606Joergensen C, Tarnow L, Goetze JP, Rossing P. Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type 1 diabetes mellitus and diabetic nephropathy: a randomized trial. Diabet Med. 2015;32(3):374-381. doi: https://doi.org/10.1111/dme.12606

The authors declare that there are no conflicts of interest present.